Erythropoietic protoporphyria (EPP) is Clinuvel's lead clinical indication for its drug SCENESSE® (afamelanotide).
This webpage is a portal for all information relevant to clinical studies and news relevant to EPP.
SCENESSE® is currently available by prescription to Italian citizens diagnosed with EPP (learn more here). Clinuvel has filed a marketing authorisation application for SCENESSE® for EPP with the European Medicines Agency (read more here). A Phase III study of SCENESSE® has been completed in the USA with results expected in the first half of 2013.